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Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma dis-
ease or as a result of transdifferentiation later in time, was described as one major process
of emerging resistance to androgen deprivation therapies, and at the clinical level it is con-
sistent with the development of rapidly progressive visceral disease, often in the absence
of elevated serum prostate-specific antigen level. Until present, platinum-based chemother-
apy has been the only treatment modality, able to produce a fair amount of responses but of
short duration. Recently, several efforts for molecular characterization of this lethal pheno-
type have resulted in identification of novel signaling factors involved in microenvironment
interactions, mitosis, and neural reprograming as potential therapeutic targets. Ongoing
clinical testing of specific inhibitors of these targets, for example, Aurora kinase A inhibitors,
in carefully selected patients and exploitation of expression changes of the target before
and after manipulation is anticipated to increase the existing data and facilitate therapeutic
decision making at this late stage of the disease when hormonal manipulations, even with
the newest androgen-directed therapies are no longer feasible.
Keywords:neuroendocrine prostate cancer, small cell prostate carcinoma, targeted therapy, androgen-independent,
castration-resistant
INTRODUCTION
For over two decades, several efforts have been made to define
and molecularly characterize the frame of neuroendocrine (NE)
prostate cancer (NEPC) presenting with distinct clinical features,
different from the classic prostatic adenocarcinoma, including fre-
quent visceral metastases, lytic bone involvement, relative low
serum prostate-specific antigen (PSA) concentration, resistance
to androgen ablation, and high response rate to platinum-based
chemotherapy (1). In the era of evolving androgen-directed ther-
apies, better molecular characterization and targeting of the NE
phenotype remains of central interest given the inherent or emerg-
ing resistance of NEPC cells to current therapies, abrogation of
which is warranted in order to improve responses and mortality
of prostate cancer (PC) patients.
NEWMORPHOLOGICAL CLASSIFICATION OF NEPC
A new histological classification for NEPC has been recently pro-
posed as a refinement of the current WHO morphologic criteria, to
better reflect the aspects of NE differentiation in PC (2). According
to the new classification, NEPC extends from usual NE differenti-
ation found in usual prostate adenocarcinoma to mixed (small or
large cell) NE carcinoma with acinar adenocarcinoma, adenocar-
cinoma with Paneth cell NE differentiation, carcinoid tumor, and
small cell carcinoma. The new classification also satisfies the previ-
ously unmet need of characterizing treatment-induced androgen
receptor (AR)-independent PC, which is a significant part of the
broader category of castration-resistant tumors clinically defined
aggressive-variant, previously known as anaplastic PC (2).
In addition, important recommendations regarding the assess-
ment and interpretation methods have emerged. First, it is not rec-
ommended to routinely use immunohistochemical (IHC) stains to
detect any NE differentiation in an otherwise morphologically typ-
ical primary adenocarcinoma of the prostate. In contrast, in cases
of metastatic castration-resistant mixed NE-adenocarcinoma, it
is recommended that the percentage and grade of the acinar
component be provided. Regarding the sampling evaluation, the
metastatic site, and/or the histology of the sample, most suspicious
for NE differentiation should be evaluated. For confirmation of
NE differentiation, markers for NE differentiation include synap-
tophysin, chromogranin, and CD56. Finally, the IHC expression of
AR across the proposed subtypes of NEPC needs to be systemati-
cally evaluated with the aim of determining its role in classification
of these tumors (2).
CURRENT TREATMENT AND BIOMARKERS
The majority of patients with NEPC are diagnosed with locally
advanced disease, usually associated with nodal or/and distant
metastases. Most often, a cisplatin-based combination (e.g., cis-
platin plus etoposide) has been used (3). Although the optimal reg-
imen has not been established, most recent evidence from a phase
2 study of first-line carboplatin and docetaxel (CD) and second-
line etoposide and cisplatin (EP) in 120 patients with “anaplastic”
PC suggests a high response rate of short duration to platinum-
containing chemotherapies, similar to small cell PC. Seventy-four
of 113 (65.4%) and 24 of 71 (33.8%) were progression free after
four cycles of CD and EP, respectively while median overall survival
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was 16 months. Intriguingly, CEA and LDH emerged as important
prognostic indicators in this patient population, in contrast with
tissue or serum NE markers including chromogranin A (CgA),
synaprophysin, gastric releasing peptide, somatostatin, which did
not predict outcome or response to therapy (4).
Plasma anterior gradient 2 (AGR2) has been proposed as a
new promising biomarker for characterization, monitoring, and
directing therapies for patients with metastatic NEPC. AGR2 is
an epithelial marker regulated by androgens through ErbB3 bind-
ing protein 1 and Fox A transcription factors and its circulating
tumor cell (CTC) mRNA and serum protein levels were found to
be significantly elevated in patients with “anaplastic” cancer (5).
Likewise, hASH-1 gene transcription is upregulated by androgen
deprivation and is associated to the onset of an NE phenotype (6).
However, a recent review of studies on the effect of NE differentia-
tion on oncologic outcomes concludes that data are insufficient to
recommend the use of NE markers in routine practice, particularly
at early PC stage (7).
EMERGING MOLECULAR TARGETS WITHIN THE LANDSCAPE
OF NEPC DIFFERENTIATION
A plethora of different signals involving neuropeptides, growth
factors, and cytokines, are involved in the several intracellu-
lar processes including angiogenesis, cell survival, proliferation,
migration, and invasion through paracrine and autocrine path-
ways. The resulting changes in more or less all of these processes
contribute to the induction of NE differentiation in PC. The
model, which has been mostly supported among several others
proposed recognizes a role of previous treatment of hormone-
naïve PC on the natural evolutionary transformation of classic
adenocarcinoma with accumulation of new genetic alterations
including loss of tumor suppressors and amplification of onco-
genes (8). The finding of rearrangement of TMPRSS2–ERG in
NEPC supports the origin of NEPC from prostate adenocarci-
noma (8). It was thus suggested that there is an evolutionary
continuum from conventional prostate adenocarcinoma to hor-
mone naive state and finally to a CRPC/mixed state as the pre-
cursor of NEPC. NEPC has been postulated to correspond to
the “cell-autonomous” phase of PC progression, which is the lat-
est evolutionary phase following an “androgen-dependent” and
a “microenvironment-driven” phase, respectively. The underlying
molecular alterations at this point of progression to NEPC include
loss of AR and androgen-regulated protein expression, induction
of NE and neural programs, loss of tumor suppressors (TP53,
RB1, PTEN) and resultant genomic instability, as well as activa-
tion of mitotic programs involving Aurora kinase A (AURKA)
upregulation and MYCN amplification (5, 8).
Alternatively, adenocarcinoma and small cell carcinoma com-
ponents of PC may originate from a common tumor clone with
stem-like properties, or a cancer stem cell, converted into more
differentiated tumor cells that accumulated molecular alterations
driving epithelial or NE phenotypes. To date, very limited amounts
of data are supportive of normal prostatic NE cell as a cell of
origin for NE tumors (9). It is also unclear if NEPC is present
at local disease or transdifferentiates later in time. Currently, as
the clinical significance remains uncertain, it is not recommended
to routinely use IHC stains to detect any NE differentiation in
an otherwise morphologically typical primary adenocarcinoma of
the prostate (2).
TUMOR SUPPRESSOR LOSS
In both benign prostate and adenocarcinoma, the IL-8–CXCR2–
p53 pathway has been shown to be a strong growth inhibitory
signal that keeps NE cells quiescent (10). P53 mutation, likely a
result of environmental pressure from classical and novel castra-
tion strategies inhibiting AR and intratumoral androgen synthe-
sis, inactivates this pathway and leads to hyperproliferation and
aggressive behavior of the NE cells, resulting in the development of
NEPC. These findings are consistent with a clonal selection model
and indicate that clones of NE cells gain a proliferative advantage in
an androgen-deprived environment through P53 mutation (11).
Loss of RB1 by deletion is another common event in prostatic
small cell carcinoma as Rb protein loss was found by immunohis-
tochemistry in as many as 90% of small cell carcinoma cases (26
of 29) with RB1 allelic loss in 85% of cases (11 of 13). Interest-
ingly, Rb protein loss rarely occurs in high-grade acinar tumors,
suggesting that Rb loss is a critical event in the development of
small cell carcinomas and may be a useful diagnostic and potential
therapeutic target (12).
ACTIVATION OF MITOSIS
The resultant genetic instability leads to additional changes, many
of which affect cell-cycle genes, especially those related to M-phase
transition, including AURKA and Polo-like kinase 1 (PLK1). PLK1
mediates entry into mitosis as well as centrosome maturation,
spindle checkpoint activity, activation of the anaphase-promoting
complex, and eventual exit from the M-phase with the initiation of
cytokinesis (13). LNCaP androgen-independent cells were found
to have upregulation of the mitotic kinase Plk1 and other M-phase
cell-cycle proteins, which rendering them highly sensitive to PLK1
inhibition through necroptosis (14).
AURKA regulates entry into mitosis, as well as assembly of
the mitotic spindle apparatus, thereby affecting chromosome sep-
aration (15). MYCN amplification is frequently associated with
AURKA amplification. In addition, AURKA was found to stabi-
lize MYCN via interaction with the Skp1-Cullin-F-box (SCF)-type
ubiquitin ligase FBXW7 that ubiquitinates MYCN and counteracts
its degradation (16). C-MYC is also involved in NEPC and was
shown to cooperate with the Proto-oncogene serine/threonine-
protein kinase 1 (PIM1) in a SCID mice NEPC model, support-
ing the concept of targeting PIM1 (17). In line with the NEPC
mitotic reprograming, in SCPC/LCNEC xenograft models, high
expression of M-phase genes was found, including Ubiquitin-
conjugating enzyme E2 C (UBE2C), coupled with RB and cyclin
D1 loss, despite the absence of AR expression (18). A sequence of
events was therefore suggested in which loss of RB and/or cyclin D1
precede AR loss and further deregulation of the mitotic apparatus.
EPIGENETIC REGULATION CHANGES
RE1-silencing transcription factor (REST), also known as neuron-
restrictive silencer factor (NRSF) is a transcription factor that
represses neuronal differentiation, in NEPC. REST-binding sites
were found on 28 of 50 transcriptionally active genes in NEPC
and in vivo in a cohort of 218 prostate tumors, in which REST
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downregulation was observed in 50% of NEPC tumors (19). Gene
expression profiling revealed that REST not only acts to repress
neuronal genes but also genes involved in cell-cycle progression,
including AURKA (20).
Also intriguing was the discovery of an invert correlation
between REST and the protocadherin (PCDH) genes PCDH11Y
and PCDH11X (9). PCDH-PC overexpression is an early-onset
adaptive mechanism following androgen deprivation therapy
(ADT) and results in attenuation of the ligand-dependent activity
of the AR, enabling certain prostate tumor clones to assume a more
NE phenotype and promoting their survival under diverse stress
conditions (21) through activation of Wnt signaling and increased
nuclear beta-catenin expression (22).
In addition, downregulation of REST level relieves gene silencer
REST-mediated transcriptional repression as part of a relay mech-
anism found in IL-6 induced autophagy through activation
AMPK/mTOR pathway (23).
The epigenetic machinery involvement in NE differentiation
process is a new field of ongoing research with existing data sup-
porting a role for the inhibition of BET bromodomains in down-
regulation of MYC expression in PC cell lines and xenografts and
more importantly “downstream” of AR (24). The histone deacety-
lase EZH2 is also highly expressed in NEPC and hypermethylation
of key genes within the NEPC genome may be associated with the
cellular plasticity seen during transdifferentiation. MYC overex-
pression leads to EZH2 activation by antagonizing miR-26a and
PI3K–AKT-mediated EZH2 inhibition, resulting in suppression
of IFNGR1 and downstream JAK–STAT1 signaling with increased
cell viability and proliferation (25).
MICROENVIRONMENT CHANGES
Acquisition of endogenous IL-6 production and its possible contri-
bution to an autocrine cell growth stimulation may play an impor-
tant role during androgen-independent progression (26). IL-6
also participates in a feed-forward loop with pigment epithelium-
derived factor (PEDF) to induce NE differentiation, in which
NFκB induction elicits STAT3 activation and pro-differentiating
IL-6 expression causing further expansion of the NE communica-
tions (27). Activation of NFκB pathway is sufficient to maintain
androgen-independent growth of prostate and PC by regulating
AR action (28).
Increased paracrine release of the pro-inflammatory cytokine
macrophage migration inhibitory factor (MIF) during NE differ-
entiation in PC may facilitate cancer progression or recurrence,
especially following androgen deprivation, through stimulation of
AKT and ERK1/2 signaling pathways. Thus, MIF could represent
an attractive target for NEPC therapy (29).
Continued focal adhesion kinase (FAK) expression (and activ-
ity) emerged as an essential factor for the androgen-independent
formation of NE carcinoma in the TRAMP model (30). Tar-
geting FAK might be an appropriate strategy in the context of
arising NE phenotype in the microenvironment phase of NEPC
differentiation.
Recent studies indicate the importance of the ubiquitin ligase
Siah2 in control of NEPC and prostate adenocarcinoma harboring
NE lesions. Siah2-dependent expression and activity of HIF-1α
regulate its availability to form a transcriptional complex with
FoxA2, resulting in expression of specific target genes, including
Hes6, Sox9, and Jmjd1a, whose co-expression is sufficient for for-
mation of NE tumors and NE lesions in PC. Siah is likely the
best candidate, since its loss abolishes formation of TRAMP NE
tumors and restoring HIF expression in such tumor cells only par-
tially (30%) rescues formation of NE tumors. Menadione is a Siah2
inhibitor. Menadione treatment inhibited HIF levels in cultured
cells, increased expression of direct Siah2 targets, and inhibited
formation of melanoma xenografts. Several inhibitors directed
against HIF have been recently developed. It is of importance to
assess their effects in prostate tumor models (31). Hypoxia itself
was shown to induce NE differentiation of LNCaP cells in vitro,
which seems to be driven by the inhibition of Notch signaling
with subsequent downregulation of hairy and enhancer of split-1
(Hes1) transcription (32).
MMP-9 produced by mast cells within the tumor microenvi-
ronment enables well-differentiated adenocarcinoma outgrowth
by favoring angiogenesis and invasion to the surrounding tissue
in TRAMP mice. Upon tumor progression, well-differentiated
adenocarcinoma undergoes epithelial-mesenchymal transition
(EMT) and foci of poorly differentiated adenocarcinoma are orig-
inated. Poorly differentiated adenocarcinoma produces MMP-9
autocrinously, thus becoming independent from mast cells. In
the absence of functional mast cells (i.e., when mast cells are
inhibited and/or genetically ablated), stem cell factor (SCF) in
the prostatic environment is no longer sequestered and becomes
available for binding to c-Kit receptor on prostate stem cells. Upon
enhanced c-Kit signaling, prostate stem cells continue to prolif-
erate, undergo NE differentiation, and progress to NE tumors,
which grow fast and quickly invade the surrounding tissue. The
common expression of c-Kit by mast cells and NE clones suggests
a possible competition for the ligand SCF and offers the chance
of curing early-stage disease while preventing NE tumors using
c-Kit–targeted therapy (33, 34).
The implication of EMT in NE transdifferentiation can also
occur through the effect of Snail. LNCaP PC cells transfected with
Snail displayed increase in the NE markers,neuron-specific enolase
(NSE) and CgA, while LNCaP C-33 cells that have been previously
reported as a NE differentiation model exhibited increased expres-
sion levels of Snail protein as compared with LNCaP parental
cells. Functionally, Snail-mediated NE differentiation was associ-
ated with increased paracrine cell proliferation. The novel protea-
some inhibitor NPI-0052 (salinosporamide A) can inhibit Snail
mRNA and protein and thereby promote sensitivity to cisplatin-
and TRAIL-mediated apoptosis in DU145 PC cells. Natural prod-
ucts including flavonoids and parthenolide have also shown some
promise toward targeting Snail signaling in PC (35, 36). Likewise,
adrenomedullin, an autocrine/paracrine factor induced by andro-
gen withdrawal, stimulates the NE phenotype in LNCaP prostate
tumor cells (37).
Src kinase is another important player in the EMT process
as it is activated by several neuropeptides, including CgA, NSE,
serotonin, neurophysin, bombesin, and synaptophysin. Through
direct physical interaction with the AR, Src is able to phosphory-
late the AR and thereby induce ligand-independent AR activation
(one of the key mechanisms of castration-resistant PC) (38).
Neuropeptides, notably bombesin were also found to enhance
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early growth response 1 (Egr-1) expression leading to increased
human protease-activated receptor 1 (PAR1) expression and func-
tion directly correlating with invasiveness and the degree of PC
malignancy (39). Src is also a mediator for the NE-derived parathy-
roid hormone-related protein (PTHrP), which induces tyrosine
phosphorylation and subsequent reduced AR ubiquitination thus
increased accumulation of AR, enhancing growth of PC cells at
low levels of androgen (40).
In addition, in co-cultures of macrophages with LNCaP and
TRAMP-C2 PC cells, a feedback loop between bone morpho-
genetic protein-6 (BMP-6) derived from PC cells and IL-6 pro-
duced by macrophages, resulted in IL-6-induced NE differentia-
tion in PC cells (41).
Receptor activator of nuclear factor kappa-B ligand (RANKL)
either derived from the tumor or from the host plays a key role in
cancer bone metastasis. A small population of RANKL-expressing
cells was observed to initiate and promote cancer bone and soft
tissue metastases by recruiting bystander cells to form tumors
in bone. The mechanism underlying this recruitment appears to
involve a feed-forward mechanism in which RANKL, RANK, and
c-Met expression is increased and AR is downregulated. RANKL
alters a large transcriptional program that appears to govern
formation of the premetastatic niche as well as emergence of
osteomimetic, EMT, and stem and NE differentiation (42). When
the anti-tumor effects of the bisphosphonate zolendronic acid and
somatostatin analogs (SMS) were tested on NE carcinoma models,
zolendronic acid, but not SMS induced apoptosis and inhibition
of proliferation and migration through impaired prenylation of
Ras, thus offering the possibility of therapeutic use in the early
phase for controlling NE cells (43).
The concept of “epithelial immune cell-like transition” (EIT),
similar to NE-like transdifferentiation of prostate adenocarcinoma
cells has been proposed to describe the acquisition of immune
properties from cancer cells, which enable them to “communi-
cate” with immune cells, leading to suppression of anti-cancer
immune activity in their microenvironment and facilitation of the
expansion and malignant progression of the disease (44).
Within this context, a dendritic cell vaccine sipuleucel-T was
developed from peripheral blood mononuclear cells obtained
by leukapheresis. In randomized trials, sipuleucel-T prolonged
overall survival compared with placebo in men with minimally
symptomatic, metastatic castrate-resistant PC (CRPC). However,
sipuleucel-T did not affect the serum PSA,restricting this approach
to patients with slowly progressive disease where a relatively rapid
response to treatment is not required (45). In addition, treatment
is contraindicated in patients who are on steroids or opioids for
cancer-related pain, and should be used with caution in patients
with liver metastases. Thus, with so far available data, assessing the
impact of immunotherapy on an individual patient with NEPC
can be difficult or impossible.
UPCOMING TARGETED APPROACHES AND PREDICTIVE
TOOLS IN NEPC
In the“cell-autonomous”phase of the disease, inhibitors that affect
mitotic function may be efficacious, as opposed to earlier stages
when AR signaling affects more “classic” AR-mediated pathways.
Currently, first-line treatment for this phase is chemotherapy,
but patients become rapidly resistant to this approach. As the
molecular basis for NEPC becomes better understood, individ-
ualized therapy may be possible.
The AURKA inhibitor danusertib (PHA-739358) was tested in a
phase II clinical trial but failed to achieve the primary endpoint of
PSA response (46). However, PSA as an endpoint is unlikely to be
suitable for tumors that are in the“tumor cell-autonomous”phase.
In addition, therapeutic treatment in this trial was not directed
specifically to patients with amplified AURKA; hence, it is not cer-
tain whether better response would have been achieved by focusing
on NEPC patients with amplified AURKA (46). Also, given the
enzymatic activity of AURKA depends not only on the amount of
protein present but also on the activity of several cofactors (such as
TPX2, BORA, and Ajuba), and has numerous substrates (including
p53, BRCA1, and even AR), it is likely that the effects of AURKA
(and thus the impact of its inhibition) are dependent, at least in
part, on the activity of the cofactors and the role of its substrates
in a given cell (47). A clinical trial evaluating the AURKA inhibitor
alisertib for patients with NEPC is under way, and AURKA and
MYCN co-amplification are being explored as potential predic-
tive biomarkers and may be used to select NEPC and patients
with high-risk PC for early intervention with AURKA-targeted
therapy (48).
Dasatinib is a Src family/abl inhibitor with preclinical activity
in PC and encouraging results in phase II studies (49). However,
there was no increase in overall survival when dasatinib was given
in combination with docetaxel plus prednisone compared with
chemotherapy alone. In the phase III READY trial, 1522 men
with metastatic CRPC were randomly assigned to either dasa-
tinib with docetaxel plus prednisone or docetaxel plus prednisone
alone. With a median follow-up of 19 months, the median sur-
vival was approximately 21 months on both treatment arms. This
failure can be explained by several factors including inadequate
study design, potential pharmacokinetic interactions between
dasatinib and docetaxel, a stronger effect on stromal cells than
on epithelial cells (despite association with the epithelial-targeted
docetaxel), and the too broad specificity of inhibitory effect
of dasatinib for numerous receptor and non-receptor tyrosine
kinases (50).
PLK1 inhibitors have recently entered clinical trials for solid
tumors. BI 2536 is a PLK1 selective inhibitor that reached phase II
trial in several solid tumors, but not PC, with little efficacy (51).
Volasertib (BI 6727) is a potent and relatively selective inhibitor
for PLK1. A phase I study in patients with advanced disease
showed a favorable pharmacokinetic profile and limited toxicities
in patients with advanced solid tumors (52). Phase II studies are
ongoing. On the basis of the three-phase model, PLK1 inhibitors
might be effective in “cell-autonomous” tumors where PLK1 is
overexpressed (8).
The role of the tumor microenvironment and data supporting
MET as a potential targetable driver of NEPC was also presented
as an area of active investigation (53). Cabozantinib (XL184) is an
inhibitor of MET, VEGFR2, and RET. A phase II trial in patients
with progressive, metastatic PC provided preliminary evidence
of activity in men with bone metastases (54). Based upon these
results, two phase III trials were initiated in patients who had pro-
gressed on docetaxel and either abiraterone or enzalutamide as
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Table 1 |Targeted therapies in NEPC.
Ref. Molecular alteration Pathway/process Target Agent Result
(10, 62) TP53 mutation IL8-CXCR2-p53 p53–Mdm2 SAR405838 Tumor regression in LNCaP mouse model, Ph1 ongoing
(12, 63) RB1 deletion RB–E2F1–Mad2 Spindle disruption Paclitaxel, STLC Prolonged mitotic and increased cell death in PC3, DU145 cells
(14, 51, 52) PLK1 upregulation AURKA–PLK1–Cdc25 PLK1 BI 2536, BI 6727 Decreased proliferation and clonogenic potential of DU145, LNCaP, PC3 cells
Ph1:limited toxicity and efficacy in solid tumors, Ph2 ongoing
(15, 16, 46) AURKA, MYCN amplification MYCN–AURKA–pH3-SYP/NSE AURKA Danusertib, alisertib Ph2: 13.6% SD ≥6 mos CRPC
(17, 64, 65) c-MYC overexpression PIM1-c-MYC c-Myc, PIM1 10058-F4,
Quercetagetin
Reduced tumorigenic potentials of LNCaP and DU145 and reduced
Pim1 protein, increased synaptophysin and Ascl1 in human PC tumors with
coexpression of PIM1-c-MYC, growth inhibition of RWPE2 PC cells
(21, 22) PCDH-PC overexpression Wnt PCDH-PC PCDH-PC si-RNA Blocked NE differentiation of LNCaP, sensitized human CRPC tumors to
docetaxel
(25) EZH2 overexpression IFN–JAK–STAT1 EZH2 DZNep Pharmacologic depletion of EZH2 by the histone-methylation inhibitor DZNep
and synergistic antitumor effect with IFN-γ in DU145 cells
(66) IL-6 overexpression PEDF–NFκB–STAT3 IL-6, STAT3 Siltuximab, LLL12 Suppressed clonogenicity of stem-like cells in patients with high-grade disease
and derived murine xenograft model
(29, 67) MIF overexpression AKT/ERK MIF ISO-1 Decreased tumor volume and angiogenesis in DU145 xenografts
(30, 68) FAK overactivation Integrin-FAK FAK PF-562,271,
PF-00562271
Attenuation of FAK and AKT phosphorylation and abrogation of
docetaxel-resistance of DU145-Rx and PC3-Rx cells, TRAMP mice
(31) Siah2 overexpression HIF-1α-FoxA2-
Hes6/Sox9/Jmjd1a
Siah2 Menadione Cell death by autoschizis in DU145 cells
(33, 34,
50, 69–74)
c-Kit amplification MMP-9–SCF-c-Kit c-Kit Imatinib, dasatinib,
sunitinib, sorafenib,
masitinib, cabozantinib
Ph1imatinib: high incidence of thromboembolic events with docetaxel/
estramustine combination for CRPC. Ph2 imatinib: limited PSA response,
toxicities in biochemical failure patients Ph3 dasatinib: addition of dasatinib to
docetaxel did not improve overall survival in mCRPC. Ph3 sunitinib: plus
prednisone did not improve OS compared with prednisone alone in
docetaxel-refractory mCRPC Ph2 sorafenib: 20% PR mTTP 5.9 mos, mOS
14.6 mos. Ph2 cabozantinib: improvements in bone scans, pain, analgesic use,
measurable soft tissue disease, circulating tumor cells, and bone biomarkers,
mOS 10.8 mos
(35, 36, 75) Snail overexpression NFκB–Snail–RKIP-NSE/CgA Snail Salinosporamide A,
flavonoids, parthenolide
Inhibition of antiapoptotic gene products and chemoimmunosensitization of
DU145 cells
(37) Adrenomedullin
overexpression
CRLR–RAMP2,3–NSE Adrenomedullin KT-5823 Inhibition of neurite outgrowth in LNCaP cells
(38, 40) Src overexpression PTHrP-AR Src Dasatinib Ph3: addition of dasatinib to docetaxel did not improve overall survival in mCRPC
(Continued)
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treatment for CRPC. In the COMET-1 trial, patients were ran-
domly assigned to either cabozantinib or prednisone; the primary
endpoint was overall survival. In the COMET-2 trial, patients were
randomly assigned to cabozanitinib or mitoxantrone plus pred-
nisone and the primary endpoint was pain control. Preliminary
results from the COMET-1 trial released by the corporate sponsor
indicated that cabozantinib did not achieve a statistically signifi-
cant increase in overall survival (55). Enrollment in the COMET-2
trial was discontinued based upon these results.
MK-2206 is an oral AKT inhibitor that was tested in a phase
1 trial using a QOD, QW, or Q3W dosing schedule in combina-
tion with carboplatin and paclitaxel, docetaxel, or erlotinib, and
was well-tolerated at doses that inhibit AKT signaling. Within a
diverse population of 72 patients including breast, melanoma,
pancreas, prostate, colon, esophageal, small cell lung cancer, a par-
tial response with a PFS of 6 months was shown in a patient with
NEPC and minor responses were demonstrated in two patients
with NE pancreatic cancers (56). Randomized phase 2 studies in
specific cancer types and more homogenous cohorts are expected
before being able to draw any conclusions about the clinical effects
of MK-2206 with other standard cytotoxic or targeted treatment
options.
Two oral endothelin receptor antagonists, atrasentan and zibo-
tentan, have been extensively studied, to target the supporting
environment for metastatic growth. Multiple phase II and sub-
sequent phase III trials were conducted with both atrasentan and
zibotentan; however, none was able to show significant benefit
compared with placebo (57–61).
Given the critical roles of CTCs and EMT in PC tumorigenesis
and the current immunotherapeutic strategies targeting prostate
tumor antigens, such as sipuleucel-T, there may be a need to
design new immunotherapies targeting cancer stem cells and cells
involved in EMT.
Cumulative data on currently established and potential future
targets of NEPC therapies within corresponding pathways are
presented in Table 1. Most evidence for NEPC targets and cor-
responding targeted agents is derived from preclinical studies or
in vivo mouse models (62–68). At the clinical level, there is no
direct evidence and all data are extrapolated from studies in CRPC
(50, 69–75) (Table 1). Thus, there is an urgent need for exploita-
tion of emerging targets through design and implementation of
studies in this particular subpopulation of PC patients with NE
differentiated PC.
CONCLUSIVE REMARKS
The molecular characterization of NEPC is a challenging area
of ongoing research with encouraging new findings on potential
new targeted therapeutic approaches as well as emerging sur-
rogate biological markers for early identification of treatment
responses and failures. However, the determination of appropri-
ate target at the right timepoint within the evolving genotype and
phenotype of the disease requires constant reassessment of the
underlying molecular changes. Collection and analysis of CTCs
offers a great opportunity of repetitively studying these changes
as a non-interventional approach compared to tissue biopsy. Ulti-
mately, identification of appropriate targets within the signaling
networks that “drive” the evolution of NEPC may not only guide
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development of newer biologic treatments but may also enable
a more appropriate, in terms of sequencing, utilization of exist-
ing therapies to correspond to the underlying molecular biology,
which dictates NEPC differentiation.
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